Clinicopathological Spectrum and Treatment Outcome of Thrombotic Microangiopathy
Background: Thrombotic microangiopathy (TMA) is a rare but life-threatening disorder predominantly involving the small vessels. It is a pathological condition which consists of microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion resulting in end-organ damage predominantl...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-04-01
|
| Series: | Indian Journal of Kidney Diseases |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ijkd.ijkd_12_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850136201957212160 |
|---|---|
| author | Sarang Vijayan Swarnalatha Guditi Raja Karthik Megha Uppin Gangadhar Taduri |
| author_facet | Sarang Vijayan Swarnalatha Guditi Raja Karthik Megha Uppin Gangadhar Taduri |
| author_sort | Sarang Vijayan |
| collection | DOAJ |
| description | Background:
Thrombotic microangiopathy (TMA) is a rare but life-threatening disorder predominantly involving the small vessels. It is a pathological condition which consists of microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion resulting in end-organ damage predominantly involving kidneys and brain.
Methods:
This was a single-center retrospective cohort study of all patients diagnosed with kidney biopsy proven TMA at Nizams Institute of Medical Sciences.
Results:
During the study period of 3 years from 2018 to 2020, native kidney biopsies were done in 1014 patients. Out of these, 19 patients were diagnosed to have biopsy proven TMA. The incidence of TMA in our study was 1.87%. The most common age group was 21–40 years (79%). The most common presentation of TMA was acute kidney injury (89.4%), which includes 15.8% of pregnancy-related acute kidney injury. Malignant hypertension was the most common underlying etiology among the study subjects (31.6%). Systemic features of TMA like hemolysis were present in 47.4% of total patients. The most common autoimmune disease associated was systemic lupus erythematosus. Complement-mediated TMA was present in 21.1% of total cases. Progression to end-stage renal disease was more common in malignant hypertension-related TMA. Autoimmune and complement-mediated TMA were treated with plasma exchange and intravenous immunoglobulin
Conclusion:
TMA is a pathological entity associated with heterogeneous group of diseases with different presentations and clinical outcomes. Depending on the underlying etiology, the clinical outcomes differ. |
| format | Article |
| id | doaj-art-d55bf70d3e774bbe80530720481fa058 |
| institution | OA Journals |
| issn | 2950-0761 |
| language | English |
| publishDate | 2023-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Kidney Diseases |
| spelling | doaj-art-d55bf70d3e774bbe80530720481fa0582025-08-20T02:31:12ZengWolters Kluwer Medknow PublicationsIndian Journal of Kidney Diseases2950-07612023-04-0122465110.4103/ijkd.ijkd_12_23Clinicopathological Spectrum and Treatment Outcome of Thrombotic MicroangiopathySarang VijayanSwarnalatha GuditiRaja KarthikMegha UppinGangadhar TaduriBackground: Thrombotic microangiopathy (TMA) is a rare but life-threatening disorder predominantly involving the small vessels. It is a pathological condition which consists of microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion resulting in end-organ damage predominantly involving kidneys and brain. Methods: This was a single-center retrospective cohort study of all patients diagnosed with kidney biopsy proven TMA at Nizams Institute of Medical Sciences. Results: During the study period of 3 years from 2018 to 2020, native kidney biopsies were done in 1014 patients. Out of these, 19 patients were diagnosed to have biopsy proven TMA. The incidence of TMA in our study was 1.87%. The most common age group was 21–40 years (79%). The most common presentation of TMA was acute kidney injury (89.4%), which includes 15.8% of pregnancy-related acute kidney injury. Malignant hypertension was the most common underlying etiology among the study subjects (31.6%). Systemic features of TMA like hemolysis were present in 47.4% of total patients. The most common autoimmune disease associated was systemic lupus erythematosus. Complement-mediated TMA was present in 21.1% of total cases. Progression to end-stage renal disease was more common in malignant hypertension-related TMA. Autoimmune and complement-mediated TMA were treated with plasma exchange and intravenous immunoglobulin Conclusion: TMA is a pathological entity associated with heterogeneous group of diseases with different presentations and clinical outcomes. Depending on the underlying etiology, the clinical outcomes differ.https://journals.lww.com/10.4103/ijkd.ijkd_12_23autoimmune diseasecomplement mediatedend-stage renal diseasemalignant hypertensionthrombotic microangiopathy |
| spellingShingle | Sarang Vijayan Swarnalatha Guditi Raja Karthik Megha Uppin Gangadhar Taduri Clinicopathological Spectrum and Treatment Outcome of Thrombotic Microangiopathy Indian Journal of Kidney Diseases autoimmune disease complement mediated end-stage renal disease malignant hypertension thrombotic microangiopathy |
| title | Clinicopathological Spectrum and Treatment Outcome of Thrombotic Microangiopathy |
| title_full | Clinicopathological Spectrum and Treatment Outcome of Thrombotic Microangiopathy |
| title_fullStr | Clinicopathological Spectrum and Treatment Outcome of Thrombotic Microangiopathy |
| title_full_unstemmed | Clinicopathological Spectrum and Treatment Outcome of Thrombotic Microangiopathy |
| title_short | Clinicopathological Spectrum and Treatment Outcome of Thrombotic Microangiopathy |
| title_sort | clinicopathological spectrum and treatment outcome of thrombotic microangiopathy |
| topic | autoimmune disease complement mediated end-stage renal disease malignant hypertension thrombotic microangiopathy |
| url | https://journals.lww.com/10.4103/ijkd.ijkd_12_23 |
| work_keys_str_mv | AT sarangvijayan clinicopathologicalspectrumandtreatmentoutcomeofthromboticmicroangiopathy AT swarnalathaguditi clinicopathologicalspectrumandtreatmentoutcomeofthromboticmicroangiopathy AT rajakarthik clinicopathologicalspectrumandtreatmentoutcomeofthromboticmicroangiopathy AT meghauppin clinicopathologicalspectrumandtreatmentoutcomeofthromboticmicroangiopathy AT gangadhartaduri clinicopathologicalspectrumandtreatmentoutcomeofthromboticmicroangiopathy |